Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Recent Approvals Support Continued Research on New and Emerging ADCs Across Breast Cancer Subtypes

April 6th 2023

Stephanie L. Graff, MD, gives an overview of recently approved ADCs in TNBC and HR-positive, HER2-negative breast cancer, as well as the importance of continued research with these agents in the first-line setting.

TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPC

March 29th 2023

Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.

Novel CAR T Utility Must Be Confirmed Across Hematologic Malignancies

March 25th 2023

Craig Sauter, MD, discussed the common limitations of CAR T-cell therapy through timely referral and the existing questions for patients with LBCL who progress on CAR T-cell therapy.

Tivozanib Plus Atezolizumab Under Investigation in Immunologically Cold Tumors

March 24th 2023

The safety and efficacy of the immune checkpoint inhibitor atezolizumab plus the VEGF TKI tivozanib is being investigated in patients with unresectable or metastatic castrate-resistant prostate cancer, as well as those with several other immunologically cold tumors as part of the phase 1b/2 IMMCO-1 trial.

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer

March 20th 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

CaboPoint Data Underscore Potential for Cabozantinib Following Frontline Combination Therapy in Advanced RCC

March 16th 2023

Laurence Albigès, MD, PhD, discusses what inspired the launch of the CaboPoint study examining second-line cabozantinib in patients with advanced renal cell carcinoma, the efficacy of this approach, and the next steps for this research.

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.

Post-Hoc Analysis Provides Quantitative Evidence on Efficacy of Frontline mCRPC Treatments After Progression on Apalutamide

March 8th 2023

Boris A. Hadaschik, MD, discusses results from a post-hoc analysis of subsequent therapy for patients with nonmetastatic castration-resistant prostate cancer who progressed following treatment with apalutamide.

Updated MAGNITUDE Data Support Niraparib Combination in mCRPC and HRR Gene Alterations

March 8th 2023

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

Enfortumab Vedotin Plus Pembrolizumab May Address Unmet Need in Advanced Urothelial Cancer

March 2nd 2023

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

Effective Utilization of CD38+ Agents, IMiDs Spur Further Clinical Research in Relapsed/Refractory Myeloma

March 2nd 2023

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

Teclistamab Approval Adds to Bucket of Relapsed/Refractory Multiple Myeloma Options

February 28th 2023

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

Real-World Analysis May Clarify Role of Adjuvant Endocrine Therapy in Premenopausal HER2+ Breast Cancer

February 24th 2023

Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.

Clinical Activity With High-dose HPN217 Warrants Continued Research in R/R Multiple Myeloma

February 20th 2023

Al-Ola A. Abdallah, MD, discusses updated safety and efficacy data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population.

Therapeutic Advances Rapidly Expand the Breast Cancer Armamentarium Across Subtypes

February 20th 2023

An increasing focus on antibody-drug conjugates for HER2-positive breast cancer signals a potential shift in the standard of care for this population.

Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection

February 20th 2023

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

Adjuvant Everolimus Plus Standard ET Does Not Significantly Improve iDFS or OS in HR+ Breast Cancer

February 14th 2023

Mariana Chavez-MacGregor, MD, MSC, discussed key efficacy and safety data from the SWOG 1207 trial of adjuvant everolimus in postmenopausal patients with high-risk, hormone receptor–positive breast cancer.

Checkpoint Inhibitors, FGFR Inhibitors Lead to Continued Advancements in Biliary Tract Cancer

February 13th 2023

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

Characterization of Relapse-Defining Events Through Patient Evaluation and Advanced Imaging Improves Treatment Selection in Multiple Myeloma

February 11th 2023

Matthew Brunner, MD, discusses how key patient factors, the use of advanced imaging modalities, and the relationship between community and academic centers influence treatment approaches in relapsed/refractory multiple myeloma.